Suven Pharmaceuticals Ltd.
Snapshot View

View in App

Prices View details >>

489.75 +0.75 ▲0.2%

27 January 2023, 04:01:00 PM
Volume: 9,402

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.suvenpharm.com
Market Cap 12,506.78 Cr.
Enterprise Value(EV) 12,472.89 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 16.94 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 28.90 Trailing Twelve Months Ending 2022-09
Industry PE 32.90 Trailing Twelve Months Ending 2022-09
Book Value / Share 59.04 Trailing Twelve Months Ending 2022-09
Price to Book Value 8.29 Calculated using Price: 489.75
Dividend Yield 1.02 Period Ending 2022-03
No. of Shares Subscribed 25.46 Cr. 254,564,956 Shares
FaceValue 1
Company Profile
The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
+0.15%
1 Week
-1.05%
1 Month
-0.09%
3 Month
+18.97%
6 Month
+4.20%
1 Year
-2.94%
2 Year
+4.41%
5 Year
10 Year

Ratios View Details >>

4 years 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 18.92 37.80 30.47 30.48
Return on Capital Employed (%) 23.87 44.55 36.19 43.13
Return on Assets (%) 13.39 25.50 21.52 23.30

Balance Sheet View Details >>

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 590 845 1,181 1,527 1,503
Non Curr. Liab. 35 128 74 92 86
Curr. Liab. 191 320 322 348 216
Minority Int.
Equity & Liab. 816 1,292 1,576 1,967 1,806
Non Curr. Assets 393 781 910 702 884
Curr. Assets 423 511 667 1,265 923
Misc. Exp. not W/O
Total Assets 816 1,292 1,576 1,967 1,806

Profit Loss View Details >>

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 378 834 1,010 1,320 1,373
Other Income 1 18 14 92 104
Total Income 378 852 1,024 1,413 1,476
Total Expenditure -206 -449 -567 -739 -779
PBIDT 172 403 457 674 697
Interest -3 -23 -12 -9 -5
Depreciation -12 -24 -32 -39 -44
Taxation -49 -88 -105 -214 -217
Exceptional Items
PAT 109 269 309 413 431
Minority Interest
Share Associate 48 54 41
Other Related Items
Consolidated Net Profit 109 317 362 454 431
Adjusted EPS 12 14 18 17

Cash Flow View Details >>

Particulars 4 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 50 407 383 330
Cash Fr. Inv. -65 -413 -311 -136
Cash Fr. Finan. 26 7 -76 -156
Net Change 11 1 -5 37
Cash & Cash Eqvt 11 12 7 45

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 60.00 60.00 60.00 60.00 60.00 60.00 60.00 60.00 60.00
Public 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Mon, 16 Jan 2023
Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to intimate you that the CRISIL has assigned the following ratings to the Bank facilities of our Company as per communication received on January 16 2023.Facilities RatingLong-term Bank Facilities CRISIL A+/Watch Developing (Placed on Rating Watch with Developing Implications)Short-term Bank Facilities CRISIL A1+/Watch Developing (Placed on Rating Watch with Developing Implications)This is for your information and record.
Mon, 09 Jan 2023
Draft Letter of Offer
Kotak Mahindra Capital Company Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer for the attention of the public shareholders of Suven Pharmaceuticals Ltd ("Target Company").
Fri, 06 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 please find enclosed herewith the Confirmation Certificates issued by KFin Technologies Limited Registrar and Share Transfer Agents of the Company for the quarter ended December 31 2022.This is for your information and record.

Technical Scans View Details >>

Fri, 27 Jan 2023
High Delivery Percentage High Delivery Percentage
Opening at High Opening at High
Closing Above Previous High Closing Above Previous High
High Increase in 3 Months High Increase in 3 Months
Closing Near 20 SMA Closing Near 20 SMA

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,710.79 1,040.75 +0.1%
Divi's Laboratories Ltd. 89,875.72 3,385.55 +1.5%
Cipla Ltd. 84,895.40 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. 71,960.69 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. 61,265.20 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. 52,047.83 1,537.85 -1.3%
Abbott India Ltd. 45,216.39 21,279.00 0.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.84 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 30.03 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 32.18 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.75 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.97 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.63 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 51.28 21,279.00 0.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.70 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 7.41 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 3.74 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.27 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.24 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.17 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 16.66 21,279.00 0.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 0.00 21,279.00 0.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 21,279.00 0.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 798.70 21,279.00 0.0%

FAQ's On Suven Pharmaceuticals Ltd.

What is Suven Pharma share price?
Can I buy Suven Pharma shares now?
What is the Dividend Yield of Suven Pharma?
What is the Market Cap of Suven Pharma?
What are the key metrics to analyse Suven Pharma?
What is the 52 Week High and Low of Suven Pharma?
What is the trend of Suven Pharma share price?